| Dr Ge Ye, DPM | |
|
2180 Vineville Ave, Macon, GA 31204-3124 | |
| (478) 742-3631 | |
| Not Available |
| Full Name | Dr Ge Ye |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 24 Years |
| Location | 2180 Vineville Ave, Macon, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124036934 | NPI | - | NPPES |
| 100002074B | Medicaid | GA | |
| P00123543 | Other | GA | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 003589 (Georgia) | Secondary |
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | POD001232 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Georgia Foot And Ankle Center Pc | 1456346816 | 2 |
News Archive
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
Safety measures intended to improve bariatric surgery outcomes may impede obese minorities' access to care. This is according to a new research letter published online in the September 12 issue of JAMA which compares rates of bariatric (weight-loss) surgery for minority Medicare vs. non-Medicare patients before and after implementation of a Medicare coverage policy.
In an "Insight" feature article, Reuters examines how new information on the prevention benefits of HIV treatment and other strategies, such as male circumcision, "could finally break the back of the AIDS epidemic."
Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies.
› Verified 5 days ago
| Entity Name | Central Georgia Foot And Ankle Center Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871789800 PECOS PAC ID: 1456346816 Enrollment ID: O20040416000325 |
News Archive
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
Safety measures intended to improve bariatric surgery outcomes may impede obese minorities' access to care. This is according to a new research letter published online in the September 12 issue of JAMA which compares rates of bariatric (weight-loss) surgery for minority Medicare vs. non-Medicare patients before and after implementation of a Medicare coverage policy.
In an "Insight" feature article, Reuters examines how new information on the prevention benefits of HIV treatment and other strategies, such as male circumcision, "could finally break the back of the AIDS epidemic."
Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ge Ye, DPM 145 River Valley Trl, Kathleen, GA 31047-2139 Ph: (478) 997-9485 | Dr Ge Ye, DPM 2180 Vineville Ave, Macon, GA 31204-3124 Ph: (478) 742-3631 |
News Archive
Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
Safety measures intended to improve bariatric surgery outcomes may impede obese minorities' access to care. This is according to a new research letter published online in the September 12 issue of JAMA which compares rates of bariatric (weight-loss) surgery for minority Medicare vs. non-Medicare patients before and after implementation of a Medicare coverage policy.
In an "Insight" feature article, Reuters examines how new information on the prevention benefits of HIV treatment and other strategies, such as male circumcision, "could finally break the back of the AIDS epidemic."
Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies.
› Verified 5 days ago